1. Home
  2. CANG vs IMMP Comparison

CANG vs IMMP Comparison

Compare CANG & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cango Inc.  each representing two (2)

CANG

Cango Inc. each representing two (2)

HOLD

Current Price

$0.66

Market Cap

253.5M

Sector

Technology

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.76

Market Cap

410.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANG
IMMP
Founded
2010
1987
Country
United States
Australia
Employees
217
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.5M
410.7M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
CANG
IMMP
Price
$0.66
$2.76
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$3.00
$10.00
AVG Volume (30 Days)
761.5K
157.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4,246.86
$382.75
Revenue Next Year
$9.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$1.32
52 Week High
$5.75
$3.53

Technical Indicators

Market Signals
Indicator
CANG
IMMP
Relative Strength Index (RSI) 25.05 49.22
Support Level N/A $2.74
Resistance Level $1.58 $3.24
Average True Range (ATR) 0.08 0.13
MACD 0.00 -0.01
Stochastic Oscillator 5.41 53.22

Price Performance

Historical Comparison
CANG
IMMP

About CANG Cango Inc. each representing two (2)

Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: